Iovance Biotherapeutics, Inc. – LSE:0JDK.L
Iovance Biotherapeutics stock price today
Iovance Biotherapeutics stock price monthly change
Iovance Biotherapeutics stock price quarterly change
Iovance Biotherapeutics stock price yearly change
Iovance Biotherapeutics key metrics
Market Cap | 2.27B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.8 |
Revenue | 1.90M |
EBITDA | -430.08M |
Income | -449.64M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -22588.66% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIovance Biotherapeutics stock price history
Iovance Biotherapeutics stock forecast
Iovance Biotherapeutics financial statements
| Jun 2023 | 238K | -106.52M | -44759.66% |
|---|---|---|---|
| Sep 2023 | 469K | -113.76M | -24255.86% |
| Dec 2023 | 482K | -116.37M | -24145.02% |
| Mar 2024 | 715K | -112.97M | -15800.84% |
| Sep 2025 | 128.24M | -14.77M | -11.52% |
|---|---|---|---|
| Oct 2025 | 100.96M | -36.42M | -36.08% |
| Dec 2025 | 117.13M | -26.02M | -22.21% |
| Mar 2026 | 715K | 47.78M | 6683.43% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 757293000 | 178.72M | 23.6% |
|---|---|---|---|
| Sep 2023 | 852315000 | 178.30M | 20.92% |
| Dec 2023 | 780351000 | 195.73M | 25.08% |
| Mar 2024 | 869830000 | 189.80M | 21.82% |
| Jun 2023 | -93.95M | -156.77M | 1.02M |
|---|---|---|---|
| Sep 2023 | -84.08M | -79.01M | 202.8M |
| Dec 2023 | -83.97M | -72.84M | 962K |
| Mar 2024 | -122.27M | -111.50M | 193.57M |
Iovance Biotherapeutics alternative data
| Aug 2023 | 503 |
|---|---|
| Sep 2023 | 503 |
| Oct 2023 | 503 |
| Nov 2023 | 503 |
| Dec 2023 | 503 |
| Jan 2024 | 503 |
| Feb 2024 | 503 |
| Mar 2024 | 557 |
| Apr 2024 | 557 |
| May 2024 | 557 |
| Jun 2024 | 557 |
| Jul 2024 | 557 |
Iovance Biotherapeutics other data
| Patent |
|---|
Grant Filling date: 5 Dec 2018 Issue date: 6 Sep 2022 |
Application METHODS AND COMPOSITIONS FOR SELECTING TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY Filling date: 12 May 2020 Issue date: 11 Aug 2022 |
Grant Filling date: 17 Nov 2017 Issue date: 2 Aug 2022 |
Grant Utility: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Filling date: 28 Jul 2021 Issue date: 12 Jul 2022 |
Application Filling date: 8 Jan 2019 Issue date: 30 Jun 2022 |
Grant Filling date: 11 Dec 2021 Issue date: 28 Jun 2022 |
Application Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof Filling date: 12 Dec 2019 Issue date: 23 Jun 2022 |
Grant Filling date: 11 Dec 2021 Issue date: 21 Jun 2022 |
Grant Utility: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Filling date: 5 Jan 2018 Issue date: 14 Jun 2022 |
Grant Filling date: 9 Dec 2021 Issue date: 7 Jun 2022 |
| Insider | Compensation |
|---|---|
Dr. Maria Fardis M.B.A., Ph.D., MBA (1968) Chief Executive Officer, Pres & Director | $1,200,000 |
| Dr. Frederick G. Vogt Ph.D., Esq. (1974) Gen. Counsel & Corporation Sec. | $571,200 |
| Dr. Friedrich Graf Finckenstein M.D. (1967) Chief Medical Officer | $458,510 |
Mr. Michael C. Swartzburg Vice President of Fin. and Interim Principal Financial Officer & Principal Accounting Officer | |
Ms. Sara Pellegrino Vice President of Investor Relations & PR | |
Mr. Howard B. Johnson Senior Vice President of Corporation Devel., Alliance Management & Program Management | |
| Dr. Elma S. Hawkins Advisor to the Board |
-
What's the price of Iovance Biotherapeutics stock today?
One share of Iovance Biotherapeutics stock can currently be purchased for approximately $18.88.
-
When is Iovance Biotherapeutics's next earnings date?
Unfortunately, Iovance Biotherapeutics's (0JDK.L) next earnings date is currently unknown.
-
Does Iovance Biotherapeutics pay dividends?
No, Iovance Biotherapeutics does not pay dividends.
-
How much money does Iovance Biotherapeutics make?
Iovance Biotherapeutics has a market capitalization of 2.27B.
-
What is Iovance Biotherapeutics's stock symbol?
Iovance Biotherapeutics, Inc. is traded on the LSE under the ticker symbol "0JDK.L".
-
What is Iovance Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Iovance Biotherapeutics?
Shares of Iovance Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Iovance Biotherapeutics's key executives?
Iovance Biotherapeutics's management team includes the following people:
- Dr. Maria Fardis M.B.A., Ph.D., MBA Chief Executive Officer, Pres & Director(age: 57, pay: $1,200,000)
- Dr. Frederick G. Vogt Ph.D., Esq. Gen. Counsel & Corporation Sec.(age: 51, pay: $571,200)
- Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer(age: 58, pay: $458,510)
- Mr. Michael C. Swartzburg Vice President of Fin. and Interim Principal Financial Officer & Principal Accounting Officer
- Ms. Sara Pellegrino Vice President of Investor Relations & PR
- Mr. Howard B. Johnson Senior Vice President of Corporation Devel., Alliance Management & Program Management
- Dr. Elma S. Hawkins Advisor to the Board
-
How many employees does Iovance Biotherapeutics have?
As Jul 2024, Iovance Biotherapeutics employs 557 workers.
-
When Iovance Biotherapeutics went public?
Iovance Biotherapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Iovance Biotherapeutics's official website?
The official website for Iovance Biotherapeutics is iovance.com.
-
Where are Iovance Biotherapeutics's headquarters?
Iovance Biotherapeutics is headquartered at 825 Industrial Road, San Carlos, CA.
-
How can i contact Iovance Biotherapeutics?
Iovance Biotherapeutics's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 02607120.
Iovance Biotherapeutics company profile:
Iovance Biotherapeutics, Inc.
iovance.comLSE
557
Medical - Pharmaceuticals
Healthcare
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
San Carlos, CA 94070
:
ISIN: US4622601007
:
